CYCN · Cyclerion Therapeutics, Inc.
Substantial doubt about the company's ability to continue as a going concern.
“The Company's expectation to generate negative operating cash flows in the future and the need for additional funding to support its planned operations, raise substantial doubt regarding the Company's ability to continue as a going concern. Management's plans to alleviate the conditions that raise substantial doubt include reduced spending, and the pursuit of additional capital. Management has concluded the likelihood that its plan to successfully obtain sufficient funding, or adequately reduce expenditures, while reasonably possible, is less than probable. Accordingly, the Company has concluded that substantial doubt exists about the Company's ability to continue as a going concern.”View the 10-Q filed Aug 4, 2026
Press releases and events scraped from the company's investor relations website. Past events open our own call or event page when we host one; otherwise listings link to the original source.
Recent news
| Date | Headline |
|---|---|
| 2026-04-01 |
Cyclerion Therapeutics and Korsana Biosciences Announce Merger Agreement
Combined company to operate as Korsana Biosciences and to advance Korsana’s potential best-in-class therapeutics to treat neurodegenerative diseases Korsana’s lead program KRSA-028 is a next-generation shuttled monoclonal antibody targeting amyloid beta for the treatment of Alzheimer’s disease |
| 2026-02-17 |
Cyclerion Therapeutics Announces Progress Toward CYC-126 Phase 2 Proof-of-Concept Study with FDA Feedback and Formation of Clinical Advisory Board
–Received Positive Pre-Investigational New Drug (“IND”) Written Feedback from the U.S. Food and Drug Administration (“FDA”)– –Clinical Advisory Board (“CAB”) Includes Key Leaders across Neuropsychiatry, Anesthesiology, and Clinical Development – –Remain On Track to Initiate CYC-126's Phase 2 |
| 2026-01-05 |
Cyclerion Therapeutics Announces Strategic Agreement with Medsteer and Progress Toward Initiating Phase 2 Proof-of-Concept Study for CYC-126 in Treatment-Resistant Depression
– Cyclerion Strengthens Development of Closed-Loop Anesthetic Platform through Strategic Collaboration Agreement with Medsteer – – Comprehensive Business Update and Path to Initiating Phase 2 Proof-of-Concept (“POC”) Study in the Second Half of 2026 – – Webcast Being Held on January 6, 2026 at 8:00 |
| 2025-09-23 |
Cyclerion Announces Transformational Relaunch as a Neuropsychiatric Company
– Cyclerion Relaunches, Advancing a Phase 2–Ready Program for Millions Living with Treatment-Resistant Depression Through MIT License Agreement – – Webcast to be held September 24, 2025 at 10:30 a.m. ET – CAMBRIDGE, Mass. , Sept. 23, 2025 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. |
| 2024-12-17 |
Cyclerion’s sGC Stimulator Portfolio Generates Revenues to Enable Company Growth
Cyclerion Has Renegotiated Praliciguat License Agreement to Obtain Upfront and Near-Term Payments as well as Entered into a License Option Agreement for Olinciguat CAMBRIDGE, Mass. , Dec. 17, 2024 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), today announced an update on its |
| 2024-08-07 |
Regina Graul, Ph.D., Promoted to Chief Executive Officer
CAMBRIDGE, Mass. , Aug. 07, 2024 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), today announced that Regina Graul , Ph.D., has been promoted to Chief Executive Officer, President, and member of the Board of Directors. Since Dr. Graul joined Cyclerion as President in early December |
| 2023-12-04 |
Cyclerion Appoints Regina Graul, Ph.D., as President
– Dr. Graul will lead the rebuild of Cyclerion, bringing more than two decades of drug making experience, R&D portfolio leadership, and a deep expertise in company strategy – – Peter Hecht , Ph.D., will continue to work closely with Cyclerion leadership as a strategic consultant and longstanding |
| 2023-11-30 |
Cyclerion Strengthens Board of Directors with Experienced Company Builder and Cutting-edge Innovator
- Dina Katabi , Ph.D.: World leader in healthcare AI applications at MIT ; inventor of groundbreaking wireless devices for passive assessment of symptoms, behavior, and treatment responses in neurological and psychiatric disorders - Michael Higgins : Seasoned biopharma executive possessing |
| 2023-07-31 |
Tisento Launches with $81 Million From Top-Tier Investor Syndicate and Promising Cyclerion Assets
– Asset Purchase Agreement Closed; Cyclerion Received Equity Ownership in Tisento and Upfront Cash Payment – – Tisento Developing Zagociguat in MELAS*, a Rare Primary Mitochondrial Disease with No Approved Therapies, Leveraging Extensive Preclinical and Clinical Data Generated by Cyclerion |
| 2023-06-01 |
Cyclerion Regains Compliance with Nasdaq Minimum Bid Price Requirement
CAMBRIDGE, Mass. , June 01, 2023 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (“Cyclerion” or the “Company”) (Nasdaq: CYCN) today announced that it has received a formal notice from The Nasdaq Stock Market (Nasdaq) stating that Cyclerion has regained compliance with the $1.00 per share minimum |
Past events
| Date | Event | Type |
|---|---|---|
| 2026-08-26 | Annual Shareholder Meeting | Shareholder meeting |
| 2026-04-01 | Earnings conference call (announced in 8-K) | Earnings call |
| 2026-01-06 | Medsteer Collaboration Agreement and Business Update | Event |
| 2025-09-24 | Pioneering a New Era in Neuropsychiatric Therapies | Event |
| 2022-07-28 | Clinical Data Update from Study of CY6463 in CIAS | Event |
| 2022-06-28 | CY6463 MELAS Study Clinical Data Update Webinar (hosted by UMDF) | Event |
| 2022-06-10 | UMDF Mitochondrial Medicine 2022 Symposium: Clinical Trial Updates with Discussion Panel Topline CY6463 Clinical Data in MELAS | Event |
| 2021-11-18 | Jefferies London Healthcare Conference | Conference |
| 2021-09-30 | Cantor Fitzgerald Virtual Global Healthcare Conference | Conference |
| 2021-09-13 | H.C. Wainwright 23rd Annual Global Investment Conference | Conference |
| 2021-08-26 | Biomarker for Alzheimer’s Disease Summit | Event |